The itinerary of Streptococcus gallolyticus infection in patients with colonic malignant disease

被引:143
作者
Boleij, Annemarie [1 ,2 ,3 ]
Tjalsma, Harold [1 ,2 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Nijmegen Inst Infect Inflammat & Immun N4i, Dept Lab Med, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Radboud Univ Ctr Oncol, NL-6500 HB Nijmegen, Netherlands
[3] Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA
关键词
COLORECTAL-CANCER; SUBSP GALLOLYTICUS; GASTROINTESTINAL-TRACT; IMMUNE-RESPONSE; FECAL CARRIAGE; BOVIS; ASSOCIATION; ENDOCARDITIS; BACTERIA; RISK;
D O I
10.1016/S1473-3099(13)70107-5
中图分类号
R51 [传染病];
学科分类号
100201 [内科学];
摘要
Bacteria constitute about 90% of all cells in the human body. The densest and most complex bacterial community is in the large intestine. This population is quite stable in healthy intestines, but intestinal disease distorts the ecological balance and induces dysbiosis. Results of studies have indicated that the epithelial and metabolic changes that occur with colorectal cancer provide a competitive advantage to a subset of intestinal bacteria. Strikingly, however, Streptococcus gallolyticus gallolyticus (previously known as Streptococcus bovis biotype I) is one of the very few opportunistic pathogens that has been clinically linked to colonic malignant diseases. In this Personal View we describe how S gallolyticus gallolyticus exploits its unique range of virulence features to cause infections in patients with colorectal cancer. We postulate that distinct virulence factors on one hand enable this bacterium to establish a symptomatic infection in susceptible individuals, and on the other hand make its ability to do this dependent on preexisting colonic abnormalities. We believe that our current reconstruction of this route of infection aids understanding of how S gallolyticus gallolyticus infections can be best exploited for early detection of colorectal cancer.
引用
收藏
页码:719 / 724
页数:6
相关论文
共 74 条
[1]
Molecular detection, quantification, and isolation of Streptococcus gallolyticus bacteria colonizing colorectal tumors: inflammation-driven potential of carcinogenesis via IL-1, COX-2, and IL-8 [J].
Abdulamir, Ahmed S. ;
Hafidh, Rand R. ;
Abu Bakar, Fatimah .
MOLECULAR CANCER, 2010, 9 :249
[2]
Investigation into the controversial association of Streptococcus gallolyticus with colorectal cancer and adenoma [J].
Abdulamir, Ahmed S. ;
Hafidh, Rand R. ;
Mahdi, Layla K. ;
Al-jeboori, Tarik ;
Abubaker, Fatimah .
BMC CANCER, 2009, 9
[3]
Al-Jashamy K, 2010, ASIAN PAC J CANCER P, V11, P1765
[4]
Araki Y, 2003, CANCER RES, V63, P728
[5]
Crypt stem cells as the cells-of-origin of intestinal cancer [J].
Barker, Nick ;
Ridgway, Rachel A. ;
van Es, Johan H. ;
van de Wetering, Marc ;
Begthel, Harry ;
van den Born, Maaike ;
Danenberg, Esther ;
Clarke, Alan R. ;
Sansom, Owen J. ;
Clevers, Hans .
NATURE, 2009, 457 (7229) :608-U119
[6]
Comprehensive study of strains previously designated Streptococcus bovis consecutively isolated from human blood cultures and emended description of Streptococcus gallolyticus and Streptococcus infantarius subsp coli [J].
Beck, Marcella ;
Frodl, Reinhard ;
Funke, Guido .
JOURNAL OF CLINICAL MICROBIOLOGY, 2008, 46 (09) :2966-2972
[7]
Carcinogenic properties of proteins with pro-inflammatory activity from Streptococcus infantarius (formerly S.bovis) [J].
Biarc, J ;
Nguyen, IS ;
Pini, A ;
Gossé, F ;
Richert, S ;
Thiersé, D ;
Van Dorsselaer, A ;
Leize-Wagner, E ;
Raul, F ;
Klein, JP ;
Schöller-Guinard, M .
CARCINOGENESIS, 2004, 25 (08) :1477-1484
[8]
Boleij A, 2011, CANCER PREV RES, V5, P260
[9]
Bacterial Responses to a Simulated Colon Tumor Microenvironment [J].
Boleij, Annemarie ;
Dutilh, Bas E. ;
Kortman, Guus A. M. ;
Roelofs, Rian ;
Laarakkers, Coby M. ;
Engelke, Udo F. ;
Tjalsma, Harold .
MOLECULAR & CELLULAR PROTEOMICS, 2012, 11 (10) :851-862
[10]
Gut bacteria in health and disease: a survey on the interface between intestinal microbiology and colorectal cancer [J].
Boleij, Annemarie ;
Tjalsma, Harold .
BIOLOGICAL REVIEWS, 2012, 87 (03) :701-730